Why Manufacturing Is Becoming the Bottleneck in Biologics

A recent Accenture report found that 64% of drug launch delays between 2019 and 2024 were caused by chemistry, manufacturing, and control issues. Not clinical failures. Not regulatory pushback on efficacy data. Manufacturing.

At the same time, biologics now represent 55% of the industry's clinical pipeline. These are molecules that are fundamentally more complex to manufacture than traditional small molecules, requiring living systems, specialized infrastructure, and a level of process control that leaves very little room for error.

Put those two data points together and the picture is clear: the industry's pipeline is getting harder to manufacture at the exact moment that manufacturing is already the primary reason drugs don't make it to market on time. This isn't a future problem. It's happening now.

Discovery Is Outpacing Manufacturing

The pace of drug discovery and clinical development has accelerated dramatically. AI-augmented research is compressing timelines. Adaptive trial designs are getting molecules into patients faster. Regulatory pathways like accelerated approval and breakthrough therapy designation are shortening the distance from Phase I to submission.

Manufacturing hasn't kept up. The same process development, tech transfer, and scale-up challenges that existed a decade ago still exist today. A biologics manufacturing process can't be rushed the way a clinical program can. Cell line development takes the time it takes. Process characterization takes the time it takes. Validation takes the time it takes. These are fundamentally sequential activities with hard dependencies, and no amount of urgency from the commercial or clinical side changes that.

What's happening is a growing gap between the speed at which programs move through clinical development and the speed at which manufacturing can be ready to support approval and launch. Companies that don't recognize this gap early end up discovering it at the worst possible time: when the BLA is filed and the supply chain isn't ready.

Biologics Are a Different Manufacturing Challenge

For anyone who has spent their career in small molecule manufacturing, the transition to biologics can be a rude awakening. Small molecules are chemical reactions. They're reproducible, well-characterized, and relatively straightforward to scale. Biologics are living systems. They're sensitive to environmental conditions, difficult to characterize fully, and the relationship between process and product is far more nuanced.

A small change in cell culture conditions can affect product quality in ways that aren't immediately obvious. Raw material variability can introduce batch-to-batch differences that require extensive investigation. The analytical methods needed to characterize a biologic are more complex, more time-consuming, and more expensive than their small molecule equivalents. And the regulatory expectations for demonstrating process understanding and control are correspondingly higher.

This complexity compounds at every stage. Process development takes longer. Tech transfers are more difficult because the process is more sensitive to site-specific differences. Scale-up introduces risks that don't exist at bench scale. And commercial manufacturing requires a level of operational discipline and process control that many organizations, particularly smaller biotechs manufacturing their first biologic, have never had to achieve before.

None of this is new information to people who work in biologics manufacturing. But it's consistently underestimated by the broader organizations that depend on manufacturing to deliver on their timelines.

Manufacturing as an Afterthought

In my experience, the root cause of most manufacturing-related launch delays isn't technical. It's organizational. Manufacturing and supply chain are treated as downstream functions that will figure it out once the science and the regulatory path are established. They get brought into the conversation late, resourced last, and expected to deliver on timelines they had no input in setting.

This is the pattern I've seen over and over across biotech companies of all sizes. The clinical program is the priority. The regulatory strategy is the priority. Manufacturing is the thing that happens after those are figured out. And by the time someone realizes that the manufacturing timeline is the constraint, significant time has been lost.

The Jefferies analysis of FDA complete response letters reinforces this. More than half of all drug rejections cite manufacturing concerns. 41% involve product quality issues. These aren't rare events. They're the most common failure mode in the approval process. And many of them are preventable if manufacturing gets the attention, the resources, and the organizational priority it needs earlier in the program's life.

What Changes When Companies Get This Right

The companies I've seen navigate biologics manufacturing successfully share a common trait: they treat manufacturing as a strategic function, not a support function. That distinction sounds subtle but it changes everything about how decisions get made.

When manufacturing has a seat at the table from the beginning of a program, process development starts earlier. CMO selection is informed by manufacturing complexity, not just cost or availability. Tech transfer timelines are built into the program plan rather than squeezed in at the end. And the cross-functional team develops a shared understanding of what the manufacturing timeline actually requires, which prevents the false expectations that lead to last-minute surprises.

It also means investing in manufacturing talent and infrastructure before the program demands it. Hiring experienced process development and manufacturing operations professionals early. Building relationships with CMOs that have the technical capability and capacity to support complex biologics. Standing up quality systems and analytical capabilities that can support the rigor biologics require.

These investments feel premature to organizations that are focused on getting through the next clinical milestone. They feel like the right call to organizations that have been through a launch delay because manufacturing wasn't ready.

The Urgency Is Real

The industry is moving toward more complex molecules, not fewer. Cell and gene therapies, bispecific antibodies, antibody-drug conjugates, mRNA-based therapeutics. Each of these modalities brings its own manufacturing challenges that are equal to or greater than traditional biologics. The manufacturing complexity curve is steepening, and the organizations that don't invest in manufacturing capability now will find themselves increasingly constrained as their pipelines advance.

Meanwhile, the external environment isn't getting easier. FDA staffing challenges are making regulatory timelines less predictable. Reshoring pressures are forcing companies to rethink their manufacturing networks. CMO capacity for complex biologics is tightening as more programs compete for the same specialized facilities.

Manufacturing has always been important. What's changed is that it's now the most common point of failure in getting a drug to market. The data is unambiguous. The companies that treat manufacturing with the same strategic priority as clinical development and regulatory affairs will be the ones that get their therapies to patients. The ones that continue to treat it as an afterthought will keep showing up in the FDA's complete response letters.

Verant Consulting Group helps biotech companies build manufacturing and supply chain strategies that keep pace with their clinical programs. From CMO selection and tech transfer planning to commercial launch readiness, we work alongside teams to make sure manufacturing isn't the thing that slows you down. Let's talk about where your program stands.